Our top pick for
BIOLASE, Inc is a medical devices business based in the US. BIOLASE shares (BIOL) are listed on the NASDAQ and all prices are listed in US Dollars. BIOLASE employs 157 staff and has a trailing 12-month revenue of around USD$24.4 million.
|52-week range||USD$0.211 - USD$1.51|
|50-day moving average||USD$1.1118|
|200-day moving average||USD$0.5132|
|Wall St. target price||USD$1.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.977|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$24.4 million|
|Gross profit TTM||USD$14.3 million|
|Return on assets TTM||-28.54%|
|Return on equity TTM||-223.29%|
|Market capitalisation||USD$140.8 million|
TTM: trailing 12 months
There are currently 9.0 million BIOLASE shares held short by investors – that's known as BIOLASE's "short interest". This figure is 10.1% up from 8.2 million last month.
There are a few different ways that this level of interest in shorting BIOLASE shares can be evaluated.
BIOLASE's "short interest ratio" (SIR) is the quantity of BIOLASE shares currently shorted divided by the average quantity of BIOLASE shares traded daily (recently around 64.2 million). BIOLASE's SIR currently stands at 0.14. In other words for every 100,000 BIOLASE shares traded daily on the market, roughly 140 shares are currently held short.
However BIOLASE's short interest can also be evaluated against the total number of BIOLASE shares, or, against the total number of tradable BIOLASE shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case BIOLASE's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 BIOLASE shares in existence, roughly 60 shares are currently held short) or 0.0623% of the tradable shares (for every 100,000 tradable BIOLASE shares, roughly 62 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against BIOLASE.
Find out more about how you can short BIOLASE stock.
We're not expecting BIOLASE to pay a dividend over the next 12 months.
BIOLASE's shares were split on a 1:5 basis on 11 May 2018. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BIOLASE shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for BIOLASE shares which in turn could have impacted BIOLASE's share price.
Over the last 12 months, BIOLASE's shares have ranged in value from as little as $0.211 up to $1.51. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BIOLASE's is 1.7519. This would suggest that BIOLASE's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems to perform soft tissue, hygiene, cosmetic procedures, and teeth whitening, as well as to provide temporary pain relief; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.